{
    "nct_id": "NCT06463340",
    "official_title": "A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.",
    "inclusion_criteria": "* Diagnosis of advanced/metastatic solid tumor\n* Measurable disease per RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments/procedures\n* Adequate bone marrow and organ function\n* Women of child-bearing potential (WOCBP) or males must agree to use highly effective contraception for the duration of study and for 90 days after the last dose of study drug\n\nExclusion Criteria\n\n* Participants with primary Central Nervous System (CNS tumors).\n* Participant has received prior systemic anti-cancer treatments or other investigational agents ≤ 21 days of first dose of study drug, or 5 half-lives, whichever is shorter\n* Participant who has received definitive local control radiation (any dose greater than 50 Gy) < 42 days prior to the first dose of study drug.\n* Participant who has received major surgeries ≤ 21 days prior to first dose of study drug\n* Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade 2 alopecia, peripheral neuropathy and ototoxicity.\n* Participant who has another clinically significant invasive malignancy, as determined by the investigator, ≤ 2 years prior to the first dose\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}